FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008712121> ?p ?o ?g. }

• W2008712121 endingPage "3660" @default.
• W2008712121 startingPage "3648" @default.
• W2008712121 abstract "Abstract Epidemiological studies demonstrate that the incidence and mortality rates of colorectal cancer in women are lower than in men. However, it is unknown if 17β‐estradiol (E 2 ) treatment is sufficient to inhibit cell proliferation and cell migration in human colon cancer cells. Up‐regulation of urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA), and matrix metallopeptidases (MMPs) is reported to associate with the development of cancer cell mobility, metastasis, and subsequent malignant tumor. In the present study, we treated human LoVo colon cancer cells with E 2 to explore whether E 2 down‐regulates cell proliferation and migration, and to identify the precise molecular and cellular mechanisms behind the down‐regulatory responses. Here, we found that E 2 treatment decreased cell proliferation and cell cycle‐regulating factors such as cyclin A, cyclin D1 and cyclin E. At the same time, E 2 significantly inhibited cell migration and migration‐related factors such as uPA, tPA, MMP‐2, and MMP‐9. However, E 2 treatment showed no effects on upregulating expression of plasminogen activator inhibitor‐1 (PAI‐1), tissue inhibitor of metalloproteinase‐1, ‐2, ‐3, and ‐4 (TIMP‐1, ‐2, ‐3, and ‐4). After administration of inhibitors including QNZ (NFκB inhibitor), LY294002 (Akt activation inhibitor), U0126 (ERK1/2 inhibitor), SB203580 (p38 MAPK inhibitor) or SP600125 (JNK1/2 inhibitor), E 2 ‐downregulated cell migration and expression of MMP‐2 and MMP‐9 in LoVo cells is markedly inhibited only by p38 MAPK inhibitors, SB203580. Application of specific target gene siRNA (ERα, ERβ, p38α, and p38β) to LoVo cells further confirmed that p38 MAPK mediates E 2 /ERs inhibition of MMP‐2 and ‐9 expression and cell motility in LoVo cells. Collectively, these results suggest that E 2 treatment down‐regulates cell proliferation by modulating the expression of cyclin A, cyclin D1 and cyclin E. E 2 treatment simultaneously impaired cell migration by inhibiting the expression of uPA, tPA, MMP‐2, and MMP‐9 through E 2 /ERs − p38α MAPK signaling pathway in human LoVo colon cancer cells. J. Cell. Physiol. 227: 3648–3660, 2012. © 2012 Wiley Periodicals, Inc." @default.
• W2008712121 created "2016-06-24" @default.
• W2008712121 creator A5011343586 @default.
• W2008712121 creator A5013290169 @default.
• W2008712121 creator A5026102216 @default.
• W2008712121 creator A5032006263 @default.
• W2008712121 creator A5032661723 @default.
• W2008712121 creator A5035267039 @default.
• W2008712121 creator A5047609838 @default.
• W2008712121 creator A5056401612 @default.
• W2008712121 creator A5060295818 @default.
• W2008712121 creator A5069308006 @default.
• W2008712121 creator A5074006227 @default.
• W2008712121 date "2012-07-19" @default.
• W2008712121 modified "2023-10-12" @default.
• W2008712121 title "p38α MAPK mediates 17β-estradiol inhibition of MMP-2 and -9 expression and cell migration in human lovo colon cancer cells" @default.
• W2008712121 cites W1507953053 @default.
• W2008712121 cites W170289634 @default.
• W2008712121 cites W1965800960 @default.
• W2008712121 cites W1967255096 @default.
• W2008712121 cites W1978309686 @default.
• W2008712121 cites W1979368995 @default.
• W2008712121 cites W1979543809 @default.
• W2008712121 cites W1982272505 @default.
• W2008712121 cites W1983478108 @default.
• W2008712121 cites W1984483611 @default.
• W2008712121 cites W1996071034 @default.
• W2008712121 cites W2002579690 @default.
• W2008712121 cites W2004101410 @default.
• W2008712121 cites W2005547107 @default.
• W2008712121 cites W2008353852 @default.
• W2008712121 cites W2010397777 @default.
• W2008712121 cites W2013656579 @default.
• W2008712121 cites W2015674806 @default.
• W2008712121 cites W2019660215 @default.
• W2008712121 cites W2022359531 @default.
• W2008712121 cites W2023576344 @default.
• W2008712121 cites W2036364900 @default.
• W2008712121 cites W2044573147 @default.
• W2008712121 cites W2058680827 @default.
• W2008712121 cites W2068428664 @default.
• W2008712121 cites W2071923574 @default.
• W2008712121 cites W2078212084 @default.
• W2008712121 cites W2078707165 @default.
• W2008712121 cites W2081511696 @default.
• W2008712121 cites W2082722418 @default.
• W2008712121 cites W2084147994 @default.
• W2008712121 cites W2097128357 @default.
• W2008712121 cites W2107969401 @default.
• W2008712121 cites W2124450232 @default.
• W2008712121 cites W2124572106 @default.
• W2008712121 cites W2125126707 @default.
• W2008712121 cites W2130696398 @default.
• W2008712121 cites W2135511773 @default.
• W2008712121 cites W2150111959 @default.
• W2008712121 cites W2158234508 @default.
• W2008712121 cites W2162004190 @default.
• W2008712121 cites W2164414963 @default.
• W2008712121 cites W2169294680 @default.
• W2008712121 cites W2169460990 @default.
• W2008712121 cites W2170661611 @default.
• W2008712121 cites W299858332 @default.
• W2008712121 doi "https://doi.org/10.1002/jcp.24072" @default.
• W2008712121 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22377968" @default.
• W2008712121 hasPublicationYear "2012" @default.
• W2008712121 type Work @default.
• W2008712121 sameAs 2008712121 @default.
• W2008712121 citedByCount "32" @default.
• W2008712121 countsByYear W20087121212012 @default.
• W2008712121 countsByYear W20087121212013 @default.
• W2008712121 countsByYear W20087121212014 @default.
• W2008712121 countsByYear W20087121212015 @default.
• W2008712121 countsByYear W20087121212016 @default.
• W2008712121 countsByYear W20087121212017 @default.
• W2008712121 countsByYear W20087121212018 @default.
• W2008712121 countsByYear W20087121212019 @default.
• W2008712121 countsByYear W20087121212021 @default.
• W2008712121 countsByYear W20087121212022 @default.
• W2008712121 countsByYear W20087121212023 @default.
• W2008712121 crossrefType "journal-article" @default.
• W2008712121 hasAuthorship W2008712121A5011343586 @default.
• W2008712121 hasAuthorship W2008712121A5013290169 @default.
• W2008712121 hasAuthorship W2008712121A5026102216 @default.
• W2008712121 hasAuthorship W2008712121A5032006263 @default.
• W2008712121 hasAuthorship W2008712121A5032661723 @default.
• W2008712121 hasAuthorship W2008712121A5035267039 @default.
• W2008712121 hasAuthorship W2008712121A5047609838 @default.
• W2008712121 hasAuthorship W2008712121A5056401612 @default.
• W2008712121 hasAuthorship W2008712121A5060295818 @default.
• W2008712121 hasAuthorship W2008712121A5069308006 @default.
• W2008712121 hasAuthorship W2008712121A5074006227 @default.
• W2008712121 hasConcept C11882975 @default.
• W2008712121 hasConcept C121608353 @default.
• W2008712121 hasConcept C126322002 @default.
• W2008712121 hasConcept C134018914 @default.
• W2008712121 hasConcept C137738243 @default.
• W2008712121 hasConcept C1491633281 @default.
• W2008712121 hasConcept C185592680 @default.

• next